The human peripheral blood contains a multipotent precursor that shows hematopoietic stem cell features and transiently expresses markers of the myeloid lineage. Under permissive conditions, this precursor gives rise to committed progenitors of various lineages, including a mesenchymal progenitor cell known by the name of fibrocyte. The fibrocytes still express some hematopoietic and myeloid antigens together with fibroblast markers. They constitutively release profibrotic and angiogenic factors and can modulate ongoing inflammatory reactions through the release of a number of chemokines. Under appropriate stimulation, fibrocytes produce increased amounts of extracellular matrix components and acquire a contractile phenotype similar to that of activated fibroblasts (myofibroblasts). Fibrocytes synthesizing new collagen or acquiring myofibroblast markers have been detected in pulmonary diseases characterized by an extensive remodeling of the bronchial wall or progressive fibrosis, in the skin of patients affected by nephrogenic systemic fibrosis, in human hypertrophic scars, in proliferative vitreoretinopathies and atherosclerotic lesions. Similar cells also participate in the stromal reaction to tumor development. Prevention of detrimental tissue remodeling in fibrotic diseases may be achieved by inhibiting the accumulation of fibrocytes. In-vitro expanded fibrocytes may be used to improve ineffective tissue repair or may be engineered for the delivery of gene constructs in anti-cancer therapy.
INTRODUCTION
Several studies have demonstrated that a small fraction of CD14 + peripheral blood mononuclear cells (PBMCs) can give rise to cells of various lineages under permissive conditions [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Such circulating CD14 + cells have been found to restore the damaged endothelium in balloon-injured femoral arteries [7] , to improve neovascularization after hindlimb ischemia [6] , and to adopt endothelial characteristics at sites of brain and skin injury [11] . Moreover, it has been reported that the administration of granulocyte colony-stimulating factor (G-CSF) after myocardial infarction in mice induces the release of a subset of CD14 + cells from the bone marrow and that these cells contribute to cardiac repair by differentiating into fibroblasts and myofibroblasts in the infarct region [12] .The subset of CD14 + cells that exhibits multidifferentiation potential likely contains a single multipotent precursor. This shows hematopoietic stem cell features and transiently expresses markers of the myeloid lineage [3, 8, 9] that may be necessary for the engraftment to peripheral organs [6, 9] . A similar cell population has been isolated from human bone marrow aspirates [8, 9, [13] [14] [15] . Moreover, a similar population of cultured bone marrow CD34 + CD14 + HLA-DR + precursors from patients with rheumatoid arthritis has shown greater ability to generate fibroblast-like cells and endothelial cells than the analogous cell population from normal individuals or patients with osteoarthritis [14, 15] . The expression of CD14 and HLD-DR is markedly down-regulated or lost during the differentiation process [14, 15] .
The fibrocyte [16] [17] [18] [19] [20] is a bone marrow-derived cell [21] [22] [23] [24] that co-expresses hematopoietic stem cell antigens, *Address correspondence to this author at the Avail Biomedical Research Institute, P. O. Box 110, CH-4003 Basel, Switzerland; Fax: +41 61 544 7374; E-mail: smattoli@avail-research.com markers of the monocyte lineage and fibroblast products [16-20, 25, 27] . This cell develops from a circulating CD14 + PBMC [18-20, 25, 26] and may represent a committed progenitor of the mesenchymal lineage originating from the multipotent precursor present in the CD14 + fraction of PBMCs [3, 8, 9] and in the bone marrow [8, 9, [13] [14] [15] . Converging evidence from several studies suggests that fibrocytes contribute to the new population of fibroblast-and myofibroblast-like cells that emerge at the tissue site during normal or aberrant wound healing [16, 18, 19, 21, 28, 29] , in ischemic or inflammatory fibrotic processes [23, 24, 27, 28, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] , and in the stromal reaction to tumor development [29, [41] [42] [43] [44] [45] [46] [47] [48] [49] . Cells exhibiting the ultrastructural or functional characteristics of fibrocytes have also been found to participate in the remodeling of the uterine cervix during pregnancy and parturition [50, 51] . This review will focus on the mechanisms and functional consequences of fibrocyte accumulation and differentiation in various human disorders and on the possible implications for cell therapy.
MECHANISMS OF FIBROCYTE DEVELOPMENT AND DIFFERENTIATION

The CD14
+ PBMC from which fibrocytes develop in cultures shows the phenotypic and functional characteristics of the circulating multipotent precursor that has been found to give rise to endothelial cells, epithelial cells, monocytes, dendritic cells, fibroblasts, osteoblasts, adipocytes or neuronal cells under permissive conditions [3, 8, 52] . In particular, this cell shows the ultrastructural characteristics of an immature progenitor and expresses stem cell/progenitor markers, including the pluripotency/self-renewal markers octamer-binding factor 4A (OCT-4A) and Nanog, in conjunction with myeloid antigens [53] (Table 1) . Like their precursors, human fibrocytes express the common leukocyte marker CD45, many markers of the monocyte lineage, the [20, 53] VEGFR2/KDR/Flk1 low -- [53] OCT-4A + low/-- [53] Nanog + -- [53] Pan-leukocyte markers CD45 + + low [16, 18, 20, 53, 54] LSP-1 NA + + [19, 28, 54] Myeloid markers CD11b + + low/- [16, 20, 27, 53] CD13 + + +/low [16, 20, 53] CD14 + low/-- [18, 19, 20, 25, 26] CD31/PECAM-1 + low/-- [53] MHC and co-stimulatory molecules MHC class II (HLA-DR) + + NA [16, 20, 27] CD80 + + NA [16, 20] CD86 + + low [16, 20] Chemokine receptors CCR2 + low/-- [20, 53, 59] CCR5 + + NA [18, 20] CCR7 + + + [18, 20, 53] CXCR4 + + + [18, 20, 34, 53] Mesenchymal markers/products Vimentin + + + [16, 20] Fibronectin -+ + [16, 20, 27] Collagens -low/+ + [16, [18] [19] [20] 27] Proteoglycans -low/+ + [57] -SMA --low/+ [18, 20, 27, 34, 54] -SMA: -smooth muscle actin, CCR: CC chemokine receptor, CXCR: CXC chemokine receptor, KDR: kinase insert domain receptor, LSP-1: leukocyte-specific protein-1, MHC: major histocompatibility complex, NA: not assessed, OCT-4A: octamer-binding factor 4A, PECAM: platelet endothelial cell adhesion molecule-1, VEGFR: vascular endothelial growth factor receptor.
class II major histocompatibility complex (MHC) molecules, the co-stimulatory molecules CD80 and CD86, the CC chemokine receptors (CCRs) CCR5 and CCR7 and the CXC chemokine receptor (CXCR) CXCR4 [16, 18, 20, 25-27, 40, 53, 54] (Table 1) . The phenotypic changes occurring during the development of fibrocytes from the CD14 + precursors include an early up-regulation of the expression of the hematopoietic stem cell/progenitor markers CD34 [40, 53] and CD105 [20, 53] on the surface of the cells (Table 1) , as the immature precursors adhere to culture plates or to the extracellular matrix (ECM) components and start proliferating [53] . The acquisition of fibroblast markers is associated with a marked down-regulation of CD14 and CCR2 expression and reduced ability to proliferate [18, 20, 25, 26, 40, 53] . The magnitude of these phenotypic changes in vitro depends on the composition of culture media and supplements [18, 20, 25, 26, 40] . A cell sharing many phenotypic characteristics with the fibrocyte, but expressing high levels of CD14 in conjunction with fibroblast products under certain culture conditions, is known as monocyte-derived mesenchymal progenitor cell [4] and may represent a more immature intermediate along the pathway that leads from the CD14 + multipotent precursor to a mature mesenchymal cell [53] . Differing from fibrocytes, this progenitor still shows mixed antigenic and ultrastructural features of immature mono-cytes, mesenchymal cells and endothelial cells and retains the ability to differentiate into non-mesenchymal cells [55] .
The signaling pathways involved in the development of fibrocytes from the CD14 + precursors and in the further differentiation of fibrocytes into mature mesenchymal cells are incompletely understood, but several factors have been identified that may promote or inhibit the process [53] (Fig. (1) ). Stimulation of peripheral blood CD14 + mononuclear cells with transforming growth factor-1 (TGF-1 ) [18, 19] , platelet-derived growth factor (PDGF) [40] and cytokines produced by helper type 2 T lymphocytes (Th2 cells), such as interleukin (IL)-4 and IL-13 [26] , promote the differentiation of the CD14 + precursors into fibrocytes. By contrast, exposure of the CD14 + precursors to immune complexes or to serum amyloid P (SAP) inhibits the development of fibrocytes [20, 25] . SAP is a constitutive serum protein that belongs to the pentraxin family of autacoids and is produced by the liver. It is present in elevated concentration at tissue sites during the early phase of inflammatory reactions, because of the extravasations of serum proteins, and it may be cleared or inactivated at a later stage [20, 25] . Interferon (IFN)-and IL-12 are cytokines normally associated with inflammatory responses mediated by helper type 1 T lymphocytes (Th1 cells) and they both inhibit the differentiation of fibrocytes from CD14 + mononuclear cells [26] . IL-1 does not affect the development of fibrocytes from the CD14 + precursors, but it reduces the release of collagens from mature fibrocytes [17] . This potent pro-inflammatory cytokine [17] and leukotriene D 4 (LTD 4 ) [56] induce a weak proliferative response in mature fibrocytes (Fig. (1) ). IFN-2b abolishes the differentiation of fibrocytes from their precursors and also inhibits the proliferation of mature fibrocytes [54] (Fig. (1) ). Interestingly, collagen-producing cells have been developed from human pro-monocytic cells (the THP-1 leukemia cell line) in cultures supplemented with IL-4, IL-13 or TGF-1 [57] .
Stimulation with TGF-1 [18, 27] and endothelin-1 (ET-1) [27] promotes the differentiation of fibrocytes into cells ultrastructurally and phenotypically similar to more mature fibroblasts and myofibroblasts (Fig. (2) ). The latter cells represent forms of activated fibroblasts that express the contractile protein -smooth muscle actin ( -SMA) but are devoid of other markers of smooth muscle cells [58] . The fibrocyte- derived population of mature fibroblast-and myofibroblastlike cells produces much more collagens and fibronectin than fibrocytes [18, 27] and lose or markedly down-regulate the expression of CD34, CD45 and most myeloid markers [18, 27, 34] (Table 1) . Spontaneous differentiation of cultured fibrocytes into -SMA positive cells may also occur in absence of exogenous stimuli [18, 20, 25, 27, 54] , particularly in long-term cultures [54] and in some serum-free media [25, 27] , and may depend on to the levels of TGF-1 constitutively released from the fibrocytes themselves [17] . IFN-2b inhibits the TGF-1 induced differentiation of fibrocytes into -SMA positive cells [54] (Fig. (2) ). Phenotypic changes similar to those observed during the differentiation of fibrocytes into cells resembling mature fibroblasts and myofibroblasts in vitro have been detected in vivo in an animal model of wound healing [21] , in a murine model of human allergic asthma with airway remodeling [27] and in animal models of vascular remodeling [37, 40] .
The fibrocytes have the potential to differentiate in vitro and in vivo into mesenchymal cells different from fibroblastand myofibroblast-like cells, such as the adipocytes [59] . The transformation of fibrocytes into adipocyte-like cells in vitro is associated with the re-expression of CCR2 and is inhibited by stimulation with TGF-1 [59] (Fig. (2) ). The fibrocytes do not acquire smooth muscle markers like the heavy-chain myosin, and are unable to differentiate into smooth muscle cells under myogenic conditions.
MECHANISMS OF FIBROCYTE ACCUMULATION AT THE TISSUE SITE
The studies that have tested for the presence of collagenproducing PBMCs in normal individuals by using more than one technique (e.g., flow cytometry and gene expression profile) have consistently indicated that freshly isolated PBMCs and CD14 + PBMC fractions from healthy subjects do not express collagen mRNAs at appreciable levels [4, 16, 18, 19] . Nonetheless, scattered CD34 + fibrocyte-like cells or cells resembling fibrocyte precursors have been detected in apparently normal tissues [49, 60] . In pathologic conditions, the maturation of fibrocytes from their CD14 + precursors may conceivably occur in the bone marrow, in the peripheral blood or at the tissue site, depending on the balance between factors that promote or inhibit such maturation process in these compartments [53] . Four studies have provided direct in vivo evidence that fibrocytes can develop from circulating CD14 + mononuclear cells at the tissue site, where they then undergo further differentiation into fibroblast-and myofibroblast-like cells. In one of these studies [24] , fibrotic cardiomyopathy was induced in mice by multiple and transient episodes of coronary artery occlusion. The development of the fibrotic changes was associated with the recruitment of CD45 + cells of the monocyte lineage from the peripheral blood, some of which subsequently expressed CD34, fibroblast markers and the myofibroblast marker -SMA. In another study [12] , G-CSF administration after myocardial infarction in mice enhanced the accumulation of bone marrow-derived fibroblasts and myofibroblasts in the ischemic area and these cells were found to arise from the mobilized subset of CD14 + mononuclear cells. In a third study [37] , the possible role of fibrocytes in the pathogenesis of chronic pulmonary hypertension was evaluated by using an animal model of hypoxia-induced pulmonary vascular remodeling.
Circulating cells of the monocyte/macrophage lineage from the chronically hypoxic rats were selectively labeled in vivo and the labeled cells were subsequently identified in the remodeled adventitial layer of the pulmonary arteries. Many of the labeled CD14 + cells recruited from the circulation progressively acquired the ability to synthesize new collagen and still retained expression of CD45 and myeloid antigens. A substantial proportion of the labeled cells also showed -SMA immunoreactivity. In a fourth study [40] , the hypothesis that fibrocytes may contribute to carotid artery intimal hyperplasia after successful revascularization procedures was tested in an ovine carotid artery patch graft model by tracking labeled peripheral blood leukocytes in the vessel wall. A small fraction of the labeled circulating leukocytes that infiltrated the intima in vivo progressively acquired the fibrocyte phenotype and showed -SMA immunoreactivity during the ongoing remodeling process.
Considering that fibrocytes may also mature in the bone marrow or in the peripheral blood and circulate as such in some pathologic conditions, several groups have used various murine models of injury-induced fibrotic reactions to evaluate the dependence of fibrocyte accumulation on the functional chemokine receptors expressed by these cells. These studies have demonstrated a significant involvement of CXCR4 [34] , CCR2 [35, 38] , CCR7 [36, 39] and CCR5 [61] . While CXCR4, CCR5, and CCR7 are expressed to various extents by both fibrocytes and their CD14 + precursors, the expression of CCR2 is markedly down-regulated during the development of fibrocytes from the CD14 + mononuclear cells ( Table 1) . In terms of level of CCR2 expression, there seem to be no major differences between murine and human fibrocytes [18, 20, 61] . Therefore, the ligands of CCR2 may be involved in the accumulation of fibrocytes at injured tissue sites mainly because they promote the recruitment of their precursors from the peripheral blood [62] .
FUNCTIONAL CONSEQUENCES OF FIBROCYTE ACCUMULATION
In all normal or aberrant repair processes and in fibrotic disorders, the major source of ECM components is represented by resident fibroblasts and myofibroblasts. However, fibrocytes [18, 21, 29, 63, 64] , fibrocyte-like cells [65] and other bone marrow-derived collagen-producing cells [65] appear to provide an additional, renewable source of lesional fibroblast-and myofibroblast-like cells during normal wound healing. In human skin wounds, CD45 + collagen I + fibrocytes are initially observed at 4 days after wounding and their number progressively increases over the following 9-10 days [29] . Fibrocyte contribution to wound healing is important because increasing the accumulation of fibrocytes at the wounded sites accelerate wound repair [63] and blocking the development of fibrocytes from their precursors by exogenous SAP reduces the efficiency of the healing process [64] . These effects are associated with a corresponding increase or reduction in the emergence of new -SMA + cells in the wounded tissue [63, 64] . Studies employing various animal models of pulmonary [34, 35, 38, 66] and renal [39] interstitial fibrosis or a model of ischemic cardiomyopathy [24] , have also provided evidence of a causal link between the accumulation of fibrocyte at injured sites and ongoing tissue fibrogenesis [53, 62] . In these models, the fibrocytes appeared to contribute to the new population of collagen-producing cells [34, 35, 38, 66] and/or -SMA positive cells [24, 39, 66] that emerged at the injured tissue sites during the fibrotic process. Inhibition of fibrocyte accumulation by various means resulted in reduced collagen deposition [24, 34, 35, 38, 39] and reduced accumulation of total -SMA positive cells [34] and fibrocyte-derived -SMA positive cells [66] . However, fibrocytes are immature mesenchymal cells that do not produce large amounts of collagenous proteins in comparison with resident fibroblasts [67] , although they release relatively high quantities of certain ECM components [53, 62] , particularly proteoglycans such as hyaluronan, perlecan and versican, and appreciable amounts of biglycan (Fig. (2) ). Moreover, it has been reported that monocyte-derived collagen-producing cells may not be able to assemble themselves the collagens they produce into the beaded filaments usually observed in the forms of interstitial fibrosis [57] , and those collagen-producing cells were developed in cultures of CD14 + PBMCs under conditions identical to those promoting the emergence of fibrocytes [18, 19, 26] . On the other hands, fibrocytes are an important source of ECM-degrading enzymes, primarily matrix metalloproteinase-9 (MMP-9) [68] , which may indirectly promote either normal or aberrant tissue repair by favoring the migration of endothelial cells and resident fibroblasts through an increased disruption of the basement membranes (BMs) (Fig.  (3) ). In addition, fibrocytes themselves produce relatively high amounts of connective tissue growth factor (CTGF) and TGF-1 [17, 67] . CTGF is known to induce the proliferation of resident fibroblasts, while TGF-1 promotes the differentiation of these cells into resident myofibroblast and the release of ECM molecules from such cells [67] (Fig. (2) ). Therefore, the reported correlations between fibrocyte accumulation and ongoing tissue fibrogenesis may also reflect the indirect pro-fibrotic activity of these cells [53, 62, 67 ]. Another important mechanism through which fibrocytes may indirectly contribute to either normal or aberrant tissue repair [53] is the release of angiogenic factors like angiogenin, basic fibroblast growth factor (bFGF), PDGF and vascular endothelial growth factor (VEGF) [68] (Fig. (3) ).
Other, often overlooked properties of fibrocytes may greatly affect the nature and outcome of local inflammatory reactions [53] . Fibrocytes express the class II MHC molecules and the co-stimulatory molecules CD80 and CD86 [16, 20, 27] (Table 1) . They exhibit antigen-presenting activity [69] but lack specific markers of monocyte-derived dendritic cells such as CD1a, CD10 and CD83 [16] . Fibrocytes are capable of priming naïve T cells both in vitro and in vivo [69] . They promote the antigen-specific proliferation of CD4 + T cells [69] and stimulate the cytotoxic activity of CD8 + T cells [70] . Therefore, fibrocytes may be involved in the initiation of adaptive immune responses and may exert a beneficial effect on the immune surveillance against viruses and tumors [53] (Fig. (3) ). These cells may also play an important role in the granulomatous reactions against parasites. A small fraction of peritoneal cells expressing monocyte markers have been reported to transform into collagenproducing cells as a result of Schistosoma mansoni infection in mice [71] . At an early stage of the differentiation process, such cells showed mixed ultrastructural and phenotypic characteristics of monocytes and fibroblasts cells. Morphologically similar cells were subsequently detected in the granulomatous livers from Schistosoma japonicum-infected mice [17] . These fibrocyte-like cells expressed CD34 and localized to areas of matrix deposition in the granulomas.
Fibrocytes may also modulate ongoing inflammatory reactions by promoting the migration and survival of various inflammatory cells through the constitutive release of a number of chemokines and growth factors [17, 53] (Fig. (3) ). The chemokines produced by fibrocytes include the CXC ligand (CXCL) 8 and CXCL1, which respectively bind to the CXCR1 and CXCR2 expressed by granulocytes [72] [73] [74] ; the CC ligand (CCL) 2, which binds to the CCR2 expressed by monocytes, natural killer (NK) cells, basophils, immature dendritic cells B lymphocytes and activated T cells [72] [73] [74] ; CCL3 and CCL4, which bind to the CCR5 expressed by fibrocytes themselves [18, 20] , monocytes, macrophages, Th1 cells, activated T lymphocytes and NK cells [72] [73] [74] [75] . Through the release of monocyte-macrophage colonystimulating factor (M-CSF) fibrocytes may promote the survival of macrophages at the tissue sites and affect their phenotypic characteristics [72, 75] . Following stimulation with IL-1 , fibrocytes also produce the pro-inflammatory cytokines IL-6 and TNF as well as anti-inflammatory factors such as the deactivator of macrophage and dendritic cell function IL-10 [17, 53] .
Involvement of Fibrocytes in Human Disorders
Airway Remodeling in Bronchial Asthma
Bronchial asthma is a very common and heterogeneous inflammatory disorder of the airways [76, 77] . The clinical course is usually characterized by recurrent episodes of wheezing and shortness of breath and persistence of bronchial hyperreactivity to a variety of inhalants in the remis- sion phases [53, 62, 78] . In most forms of asthma, the bronchial mucosa shows an inflammatory infiltrate mainly composed of Th2 cells, CD14 + monocytes, eosinophils and mast cells [79] [80] [81] . Patients with severe persistent asthma can exhibit a neutrophil-predominant inflammation of their airways [82] . The bronchial wall of asthmatic patients usually shows the signs of an ongoing remodeling process, which include the accumulation of fibroblasts and myofibroblasts beneath the epithelial BM, thickening of the lamina reticularis as a result of an excessive deposition of ECM molecules, angiogenesis, and bronchial smooth muscle cells hyperplasia/hypertrophy [80, 83] . Repeated cycles of airway inflammation and repair, with incomplete healing, may cause most of these structural alterations [36, 53, 62, 80] . Although the severity of asthma is related to the degree of airway remodeling [83] , the functional consequences of the remodeling process and their clinical relevance remain unclear [80, 83, 84] .
In patients who suffer from the allergic form of asthma, every exposure to the relevant allergens triggers an increased production of chemokines and growth factors, including CCL2, ET-1 and TGF-1 , and further recruitment of CD14 + monocytes, Th2 lymphocytes and eosinophils into the bronchial mucosa [79, [85] [86] [87] [88] . Epithelial cells are a major source of chemokines and growth factors [36, 79, 80, 89] and the inflammatory infiltrate is particularly abundant in the subepithelial area [87, 88] . The acute exacerbation of the inflammatory response is associated with the emergence of new -SMA + myofibroblast-like cells beneath the epithelial BM within 24 hours after allergen exposure [90] and is followed by an excessive deposition of ECM molecules in the lamina reticularis, which may persist for days [91] . Fibrocytes contribute to the emerging population of new -SMA + myofibroblast-like cells [27] . These cells also co-express CD34 and pro-collagen I mRNA and localize to areas of new ECM deposition beneath the epithelial BM [27] . The allergen-induced accumulation of fibrocytes in the bronchial mucosa is paralleled by an increased production of ET-1 from epithelial and endothelial cells and increased release of TGF-1 from epithelial cells and eosinophils [86] . The high levels of TGF-1 at the tissue site may promote the differentiation of fibrocytes from the CD14 + precursors recruited at an earlier stage, as a result of the increased production of the CCR2 ligand CCL2 [53, 62] . Other cytokines produced by inflammatory cells [79, 80] may also affect the expansion of the fibrocyte population at the tissue site [53, 62] . In particular, Th2 cell-derived IL-4 and IL-13 may contribute to promote the development of fibrocytes from their precursors while macrophage-and dendritic cell-derived IL-1 may induce fibrocyte proliferation [53, 62] . The peak increase in the release of ET-1 and TGF-1 in the bronchial mucosa is observed at 24 hours following allergen inhalation [86] , and may favor further differentiation of fibrocytes into new -SMA myofibroblast-like cells at this stage [27, 53, 62, 86] .
CD45
+ CD34 + fibrocytes, actively synthesizing collagenous proteins, have been reported to populate the bronchial mucosa of asthmatic patients even in the absence of an acute exacerbation of the disease [32] . Their density increases in the bronchial mucosa of patients with more severe disease, including subjects with refractory asthma [92] . Some of these fibrocytes acquire the myofibroblast phenotype, as assessed by the expression of -SMA, and can be found in clusters in the lamina propria, close to the epithelial BM, and in the airway smooth muscle bundle [32, 92] . The density of fibrocytes in the bronchial mucosa beneath the BM correlates with the thickness of the lamina reticularis [32] , supporting the hypothesis that fibrocyte-derived fibroblast-and myofibroblast-like cells contribute at least in part to the excessive deposition of ECM components in that area [53, 62, 86] . Similar cells also spontaneously emerge in cultures of bronchoalveolar mononuclear cells from asthmatic patients [32] , indicating that there are fibrocyte precursors in the inflammatory infiltrate [53, 62] . A recent study [93] has demonstrated the presence of CD45 + CD34 + CXCR4 + CCR7 + collagen I + fibrocytes in the peripheral blood of more severe asthmatic patients with chronic airflow limitation, who also have elevated levels of serum TGF- 1 . Studies in an animal model of allergen-induced airway remodeling [36] and in patients with asthma [33] support the hypothesis that the CCL19/CCR7 axis may play an important role in the recruitment of these cells to the bronchial mucosa of asthmatic individuals, if the serum concentrations of factors promoting their differentiation in the peripheral blood are sufficiently elevated [53] .
The accumulation of fibrocytes beneath the epithelial BM in asthmatic airways may cause either beneficial or detrimental effects [53, 62] . In addition to various types of collagens, fibrocytes and fibrocyte-derived more mature mesenchymal cells produce other ECM components that have been detected in vivo in the thickened lamina reticularis of asthmatic patients [94, 95] or in cultures of bronchial fibroblasts isolated from asthmatic individuals [96] , particularly the proteoglycans biglycan, hyaluronan, perlecan and versican (Fig. (2) ) The excessive deposition of ECM molecules in the lamina reticularis by fibrocytes and fibrocyte-derived fibroblast-and myofibroblast-like cells increases the thickness of the airway wall and may contribute to generate chronic airflow limitation [53, 62] . However, both this reticulin fibrosis and the contractile force generated by the -SMA positive fibrocytes may enhance the resistance to mechanical stress of a bronchial wall weakened by the inflammatory process, thereby preventing further damage during broncho-constrictive episodes [53, 62] . Moreover, it has been recently proposed [83] that the increase in ECM deposition in asthma may result in an increased stiffness of the airway wall and inhibition of mucosal folding, both of which may serve to add the loads against which airway smooth muscle shortens during an episode of bronchial constriction in order to limit, rather than increase, airway narrowing. Fibrocyte also produce ECM-degrading enzymes and pro-angiogenic factors [68] (Fig. (3) ) that would facilitate normal tissue repair but may have deleterious effects in a chronic wound-healing-like situation where neither the inflammatory phase nor the reparative phase resolve completely [53, 62] .
Human fibrocytes exhibit antigen-presenting activity [69] and may potentially capture the antigens that cross the airway epithelial barrier and present them to the CD4 + T lymphocytes residing in the lamina propria. Because of this antigen-presenting property and the ability to release a number of pro-inflammatory chemokines and growth factors (Fig.  (3) ), fibrocytes may work in concert with dendritic cells to amplify the allergic inflammatory reaction after every exposure to the relevant allergens [53, 62] . Although fibrocytes exhibit in-vitro susceptibility to virus infection and may po-tentially represent a reservoir for virus replication in the airways, they are also capable of stimulating the virus-specific proliferation and cytotoxic activity of CD8 + T lymphocytes in co-cultures [70] (Fig. (3) ). Therefore, fibrocytes may participate, either with detrimental or beneficial effects, in immune reactions that are known to contribute to the extreme exacerbations of fatal asthma [97] . In this respect, it is worth noting that the differentiation of fibrocytes into more mature mesenchymal cells occurs relatively quickly in the airway mucosa [27] and that fibrocyte-derived fibroblast-and myofibroblast-like cells may lose most of the non-mesenchymal functional properties of the cells with mixed myeloid and mesenchymal features from which they originate [53, 62] . Nonetheless, bronchial fibroblasts from asthmatic individuals show an in-vitro susceptibility to virus infection [98] similar to that of cultured fibrocytes [70] .
Idiopatic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic lung disorder of unknown etiology and represents the most common form of idiopathic interstitial pneumonia [99, 100] . It is characterized by excessive deposition of collagens in the interstitium, with progressive and irreversible fibrotic replacement of the normal lung structure [100] [101] [102] . The pathologic hallmarks of IPF are fibroblastic foci demarcated from surrounding cells, which are composed of clusters of fibroblasts and myofibroblasts [100, 103, 104] . These foci are considered as indicative of active fibrogenesis [103, 104] . The progressive loss of functional parenchyma ultimately results in respiratory failure [100] , and the disorder is often fatal within a few years from the diagnosis because the presently accepted approach to treat IPF with high-dose corticosteroids, with or without immunosuppressive agents, is ineffective in most cases [105] [106] [107] .
The lungs of patients with IPF produce high quantities of cytokines and growth factors that may promote the development and further differentiation of fibrocytes into fibroblastand myofibroblast-like cells, particularly IL-13, TGF-1 and ET-1 [108] [109] [110] [111] [112] . Four studies [113] [114] [115] [116] have evaluated the possibility that fibrocytes are involved in the pathogenesis of IPF. The first study [113] demonstrated the presence of cells co-expressing CCR7 and CD45 in the lung tissue specimens from patients with this disease. These cells did not express CD34 or -SMA and were not specifically present in areas of active collagen deposition. A diffuse pattern of CXCR4 expression was seen in all tissue specimens and most of the CXCR4 + cells appeared to be infiltrating monocytes. In the second study [114] , increased expression of the CXCR4 ligand CXCL12 was observed in lung bioptic specimens from patients with IPF but the presence of fibrocytes was not evaluated. However, these patients showed peripheral blood monocytosis and higher numbers of circulating CXCR4 + CD45
+ collagen I + cells in comparison with normal subjects. In the third study [115] , cells showing multiple phenotypic markers of fibrocytes (CD45, CD34 or CXCR4) and fibrocyte-derived -SMA + cells were identified in the lungs from 8 out of 9 patients with stable IPF by immunofluorescence analysis and confocal microscopy. Similar cells were absent in the lungs from control subjects. In the tissue specimens from patients with IPF, fibrocytes were actively synthesizing new collagen, as they expressed the intracellular form of collagen I (pro-collagen I) or prolyl-4-hydroxylase, an enzyme critically involved in collagen synthesis. These observations excluded the possibility that CD45 + fibrocytes were erroneously confused with CD45 + macrophages containing phagocytosed fragments of extracellular collagen. Moreover, they were often present in proximity of fibroblastic foci and there was a significant correlation between the density of fibrocytes and the number of fibroblastic foci in the lungs. Fibrocytes invariably expressed CXCR4 and there were elevated levels of the CXCR4 ligand CXCL12 both in the plasma and in the bronchoalveolar lavage fluid of patients with IPF. The results of the latter study clearly indicate that fibrocytes accumulate and may further differentiate into more mature mesenchymal cells in the lungs of patients with IPF and that the CXCR4/CXCL12 axis may play an important role in the intrapulmonary recruitment of fibrocytes or their precursors in this disease. The plasma levels of CXCL12 were more elevated in patients with poor gas exchange, reflecting a more severe loss of functional parenchyma. These findings suggest that the measurement of the plasma levels of this chemokine may be used as a prognosis marker in IPF and such possibility should be confirmed in a larger number of patients with various levels of lung function impairment. The fourth study [116] included 51 patients with stable IPF and a sufficient number of controls. In comparison with healthy individuals and patients with acute respiratory distress syndrome, the patients with IPF showed increased numbers of circulating CD45 + collagen I + cells by flow cytometry. Other specific surface markers of fibrocytes, or markers of cells actively synthesizing collagen, were not evaluated and the presence of similar cells in the lungs was not investigated. The numbers of circulating CD45 + collagen I + cells did not correlate with clinical parameters of disease severity (lung function and radiological severity scores). However, the mean number of circulating CD45 + collagen I + cells further increased during acute disease exacerbations and was more elevated in patients with a mean survival of only 7.5 months than in patients with a mean survival of 27 months. The results of this study are important because they suggest that quantitation of circulating CD45 + collagen I + cells may be used as a clinical marker for predicting early mortality in IPF. Therefore, further studies are needed to support the hypothesis that there is a substantial increase in the numbers of fibrocytes in the lungs of patients with poor prognosis and to evaluate the relative contribution of these cells to collagen deposition and disease progression in IPF.
Nephrogenic Systemic Fibrosis
Nephrogenic systemic fibrosis (NSF) (formerly nephrogenic fibrosing dermopathy) is a relatively uncommon disease that may develop in patients who have a marked reduction in renal function [117, 118] . The fibrotic disease affects most frequently the extremities and is characterized by the symmetric development of discolored skin papules and plaques that progress to more extreme brawny induration and thickening of the skin [118, 119] . The severity of the disease varies from one patient to another. Contractures of joints may occur and in some cases may lead to serious physical disability [118, 119] . Involvement of multiple organs has been reported in many patients and, in these cases, the fibrotic process can ultimately lead to death [117] [118] [119] . Examination of bioptic specimens shows a dense infiltrate of spindle-shaped cells, which are immersed in a network of collagen bundles [119] [120] [121] [122] [123] . Contrary to fibro-sclerotic conditions like scleroderma, clefts are usually maintained between individual collagen bundles [119] . Between the spindle-shaped cells and the collagen bundles, there is often a myxoid substance composed of mucin and immature collagen [119] . Together with abundant spindle-shaped cells, an increased number of CD68 + monocytes/macrophages, dendritic-like cells expressing factor XIIIa and mast cells may be noted in the dermis and subcutaneous tissue [119] [120] [121] [122] [123] . Some bioptic specimens may contain large number of CD68 + mononuclear cells and, more rarely, osteoclast-like giant cells and foci of osteoid deposition [119] . A mild perivascular infiltrate of monocytes is also frequently present in the bioptic specimens from patients with NSF, but neutrophils, eosinophils and lymphocytes are characteristically absent in the NSF lesions [119] . Calcifications are commonly observed within macrophages and frequently encrust the thickened collagen bundles and the elastic fibers. Signs of angiogenesis and neovascularization may be present within the septa, in the vicinity of fat lobules [119] . Patterns resembling dermal angiomatosis have also been reported [119] . Deepincision biopsies may show extension of the fibrotic process from the dermis through the fascia into the underlying skeletal muscle [118, 119] . In these cases, the skeletal muscle fibers show signs of atrophy [118, 119] . In case of multiorgan involvement, the small arterioles of the lungs and the heart can show an increased thickness of the adventitial layer and perivascular fibrosis [120] . These alterations may precede the development of a fibrotic process similar to that described in the skin.
In 2003, Cowper and Bucala demonstrated that most of the spindle-shaped cells present in the lesional skin of NSF patients were fibrocytes co-expressing CD45 and procollagen I mRNA [31] . Subsequent studies confirmed the presence of numerous CD45 + CD34
+ collagen-producing cells in the dermal infiltrate of the lesional skin [120] [121] [122] . The various stages of maturation and further differentiation of fibrocytes in relation to collagen deposition in NSF lesions have been described in a more recently published paper [119] . In early lesions of NSF, where the collagen bundles are thin and the number of infiltrating CD34 + fibrocytes is relatively low, these cells show a weak pro-collagen-I immunoreactivity in the perinuclear cytoplasm [119] . In more advanced lesions, the collagen bundles become thicker and the cytoplasm of the fibrocytes shows intense and diffuse pro-collagen-I immunoreactivity [119] . When the fibrocyte infiltrate becomes prominent, these cells usually form a complex dendritic network and cross sections of the collagen may show that the dendritic processes of the CD34 + fibrocytes encircle the collagen bundles [119] . In some very advanced NSF lesions, it is possible to observe areas of collagen sclerosis, characterized by the loss of definition of the collagen bundles and hyalinization [119] . In these foci, the apparent decrease in the number of CD34-or CD45-positive spindle-shaped cells is mirrored by an increase in the number of myofibroblasts [119, 124, 125] , suggesting that some fibrocytes may have assumed a myofibroblast-like phenotype [124] . Because high levels of TGF-1 mRNA have been detected in the lesional skin of patients with NSF [123] , this growth factor may play a major role in the process of local maturation and further differentiation of fibrocytes described above. The fact that fibrocytes largely contribute to the pathologic alterations seen in NSF is also supported by a study that has demonstrated higher levels of hyluronan in cultures of fibroblasts from NSF patients than in fibroblast from normal controls [126] . Hyaluronan is highly expressed in cultured human fibrocytes (Fig. (2) ) and, together with immature pro-collagen I, may represent an important component of the myxoid substance that is often found between the fibrocytes and the collagen bundles in NSF lesions and that stains with typical mucin stains [119] .
The pathogenesis of NDF is still unclear [118] , but clinical data [127] and the results of experiments in an animal model of NSF [128] indicate a highly probable causal relationship between exposure of patients with marked reduction in renal function to gadolinium-based contrast agents for magnetic resonance imaging and the development of this disease. The prevalence of NSF is significantly higher after exposure to a gadolinium-based contrast agent with low stability like gadodiamide than with any other gadoliniumbased contrast agent [127] . In these molecules of low stability, the gadolinium ion (Gd 3+ ) is more likely to dissociate from its stabilizing chelate moiety than the Gd 3+ of other formulations and be replaced by an endogenous cation like zinc, calcium or iron [129] . Free Gd 3+ may then attach to endogenous anions, like phosphates, and form insoluble salts that deposit in tissues [129] . These precipitates may then trigger a series of events leading to tissue damage and accumulation of fibrocytes at tissue sites [129] . Free Gd 3+ may also directly bind collagen molecules at their helix and cause collagen fibrillogenesis [129] . Interstitial and vascular calcium deposits have been indeed described in several tissues from patients affected by NSF and may represent deposits of gadolinium with calcium phosphates [118, 119, 129] . Moreover, the presence of Gd 3+ has been demonstrated in the tissue of NSF patients by using scanning electron microscopy and energy dispersive X-ray spectroscopy [119] . NSF may predominantly occur in patients with advanced kidney disease because the very low glomerular filtration rate results in impaired renal excretion of the gadolinium-based contrast agents and consequent increase in the probability of dissociation of Gd 3+ from its chelate in the peripheral blood [118, 129] . However, NSF is uncommon even in patients with advanced kidney disease exposed to gadolinium-based contrast agents with low stability, suggesting that a number of permissive factors are required for gadolinium-based contrast media exposure to cause NSF [117, 118, 129] . These permissive factors may include pathologic conditions that allow free or bound Gd 3+ to more easily enter tissues, such as underlying vascular injury or inflammation, and factors that favor the formation of insoluble salts of gadolinium, such as elevated serum concentrations of phosphate and calcium [118, 129] . Considering the impressive accumulation of fibrocytes in NSF lesions, further studies on the pathogenesis of NSF may uncover important mechanisms involved in the accumulation of fibrocytes in this and other fibrotic conditions and may help clarify their functional role.
Post-Burn Hypertrophic Scars
Extensive burn injuries frequently lead to the development of hypertrophic scars and keloids [130, 131] , with consequent long-term disfigurement. In these cases, the tightly regulated mechanisms of wound healing do not operate effi-ciently, leading to persistent inflammation and excessive ECM deposition in the dermis [130] [131] [132] [133] [134] . The inflammatory infiltrate is particularly evident in young lesions and in the hypertrophic form, and is composed of T lymphocytes, monocytes and dendritic-like cells [133] . Collagen I, collagen III, versican and biglycan are produced in excessive amounts in both hypertrophic scars and keloids [134] . However, the fibroblasts from hypertrophic scars produce relatively low amounts of decorin, which is critically involved in the transformation of immature collagens I and III into beaded fibers [134] . Hypertrophic scars usually contain narrow and widely-spaced collagen fibrils that are arranged to form a nodular structure [132, 133] . In contrast, keloids contain thick collagen fibers composed of numerous fibrils packed together [132, 133] . The nodules of hypertrophic scars show the presence of spindle-shaped cells actively synthesizing new collagens (pro-collagen I and pro-collagen III) [134, 135] and numerous -SMA myofibroblasts, which are also thought to cause the typical scar contractures [132] . By examining the immunohistochemical characteristic of the dermal infiltrate at various stages of hypertrophic scar and keloid development, Aiba and Tagami [136] detected the presence of spindle-shaped cells co-expressing CD34 and prolyl-4-hydroxylase, the enzyme critically involved in collagen synthesis, in scars where the inflammation began to subside. They observed that CD34 expression decreased over time while the expression of prolyl-4-hydroxylase progressively increased. In a subsequent study, Yang and colleagues [28] identified spindle-shaped cells co-expressing the leukocyte-specific protein-1 (LSP-1) and pro-collagen I in postburn hypertrophic scars. Similar cells were also present in more mature scars (keloids), but their density was a significantly lower than in hypertrophic scars. LSP-1 is one of the leukocyte markers expressed by fibrocytes ( Table 1) and it is retained more stably than the transiently expressed CD34 or CD45 [19, 28, 54] . Taken together, the results of these two studies indicate that fibrocytes contribute to the lesional fibroblast population present in different forms of aberrant wound healing, particularly in post-burn hypertrophic scars, and confirm the in-vivo evidence from animal studies [21, 27] that fibrocytes progressively lose CD34 expression as they differentiate into mature mesenchymal cells. In hypertrophic scars, the local accumulation and further differentiation of fibrocytes may be favored by the presence of high levels of TGF-1 in the micro-environment because the nodules of hypertrophic scars exhibit enhanced expression of TGF-1 mRNA [135] . In patients with post-burn hypertrophic scars, the maturation of fibrocytes from their circulating precursors may also occur at least in part in the peripheral blood because elevated levels of serum TGF-1 have been detected for up to 20 days post-burn in patients with burn injuries involving 30% or more of their total body surface area [19] . Moreover, the CD14 -PBMCs from these patients spontaneously produce higher levels of TGF-1 than those from healthy individuals and have been found to up-regulate the development of fibrocytes from their CD14 + precursors in culture of unfractionated PBMCs through the release of this growth factor [19] .
Hypertrophic scars and keloids commonly recur following surgical treatment and the currently available nonsurgical methods of treatment offer minimal likelihood of improvement [134, 137] . As mentioned in a previous section, IFN-2b is an inhibitor of fibrocyte maturation and proliferation (Fig. (1) ) and blocks the fibrocyte differentiation into mature fibroblast-and myofibroblast-like cells induced by TGF-1 (Fig. (2) ). In a recent phase-II clinical trial on the efficacy and safety of IFN-2b for the treatment of post-burn hypertrophic scars [54] , systemic administration of IFN-2b significantly improved the scar quality and this beneficial effect was associated with a dramatic decrease in the number of fibrocytes at the tissue site, suggesting that fibrocytes may play an important functional role in the pathogenesis of post-burn aberrant wound healing.
Proliferative Vitreoretinopathy
Proliferative vitreoretinopathy (PVR) is a disorder caused by the formation of fibrous epiretinal membranes at the vitreoretinal interface in the vitreous cavity following retinal break and detachment [138] [139] [140] [141] , and it is considered a form of aberrant wound healing [140] [141] [142] . The fibrotic process reduces the flexibility of the retina and represents a major cause of failure to reattach it by surgery [138] [139] [140] [141] . The core of the fibrous membranes contains high numbers of -SMA + myofibroblasts of unclear origin, which produce excessive amounts of ECM proteins and cause progressive contraction of the granulation tissue [143] [144] [145] . A recent study evaluated the phenotype of the myofibroblast present in 16 epiretinal membranes from patients undergoing vitreoretinal surgery for the treatment of retinal detachment complicated by PVR [146] . The immunohistochemical analysis of the cell infiltrate revealed that fibrocyte-derived -SMA + cells substantially contributed to the myofibroblast population [146] . On the basis of the data published by the investigators, it is possible to estimate that, on the average, 13% to 33% of the -SMA + cells present in the epiretinal membranes coexpressed CD34, CCR7 or CD45. A higher proportion of the -SMA + myofibroblasts showed CXCR4 immunoreactivity. The epiretinal membranes also contained increased numbers of cells expressing the CXCR4 ligand, CXCL12, and the CCR7 ligand, CCL21 [146] . Considering the results of previous in-vitro and in-vivo studies [21, 27] , it is reasonable to think that CXCR4 + CD45 + CD34 + -SMA + cells likely represent the most immature fibrocyte-derived myofibroblast-like cells while CXCR4 + CD45 -CD34 --SMA + cells are mature mesenchymal cells that have lost hematopoietic and myeloid markers as result of the differentiation process. In the epiretinal membranes from patients with PVR, the density of the CD34 + myofibroblasts significantly correlated with the numbers of CXCL12-and CCL21-positive cells [146] , suggesting that both CXCL12 and CCL21 had been actively recruiting fibrocytes or their precursors to the eye during the development of PVR. Several pro-fibrotic growth factors and cytokines are produced in excessive amounts by astrocytes and retinal pigment epithelia cells during the development and progression of the fibrotic process in PVR. These include various TGF-isoforms, PDGF and ET-1 [143, [147] [148] [149] . Elevated concentrations of TGF-, PDGF and ET-1 have been detected in the vitreous humor of patients with PVR [143, 147, 148] , and the levels of TGF-and PDGF correlate with the severity of the fibrotic process [143, 147] . Moreover, myofibroblasts expressing the ET-1 receptor B have been detected in the fibrous core of human epiretinal membranes [149] and blockade of this receptor prevents experimentally-induced PVR development in mice [149] . Be-cause PDGF,TGF-and ET-1 are known to promote the maturation (Fig. (1) ) and further differentiation of fibrocytes (Fig. (2) ), their documented involvement in the pathogenesis of PVR may at least in part be related to their effects on fibrocytes.
Atherosclerosis
Atherosclerosis is an inflammatory disease that involves the wall of the large-and medium-sized arteries, and predominantly affects the vessel zones mostly exposed to mechanical stress [150] [151] [152] . The initial endothelial damage triggers a series of events that ultimately result in the formation of an atheroma in the intima of these arteries [150] [151] [152] [153] [154] [155] [156] . The atheroma is composed of a fatty core, mainly containing foam cells and extracellular lipids [150, 152, 154, 155] . The intimal area overlaying the core initially contains foam cells and isolated myofibroblasts synthesizing new collagen [154, 155] . In more advanced lesions, there is a marked increase in the number of myofibroblasts in this zone, and the excessive deposition of collagen and other ECM molecules from these cells leads to the formation of a fibrous cap [154, 155] . This remodeling process may be either expansive or constrictive in nature, and in both cases it causes luminal narrowing with consequent tissue ischemia [156] . Atherosclerotic plaques having a large fat core and thin fibrous cap are more unstable than plaques with a thick fibrous cap and a small fatty core [157, 158] . They easily rupture and can cause an acute obstruction of the vessel or generate emboli by exposing or releasing the highly thrombogenic content of the core [157, 158] . Through the production of ECM components and their contractile properties, the myofibroblasts in the fibrous cap stabilize the plaque. These beneficial effects may outweigh the detrimental increase in plaque volume resulting from the excessive ECM deposition [53, 62] .
Fibrocytes co-expressing pro-collagen I and CD34 or pro-collagen I and LSP-1 were recently identified in the fibrous cap of atherosclerotic lesions in human carotid arteries [159] . These cells also showed CD68 immunoreactivity, a finding consistent with the origin of fibrocytes from a precursor of the monocyte lineage. Some of the CD34 fibrocytes expressed the myofibroblast marker -SMA but did not express smooth muscle cell markers such as smoothelin or the myosin heavy chain 1. Fibrocytes were detected in areas of the plaque showing intense TGF-1 immunoreactivity and also in proximity of recent plaque fractures. They were absent in areas of the plaque that stained positively for SAP. One previous study [160] had demonstrated the presence of cells co-expressing the monocyte marker CD68 and pro-collagen VIII mRNA in the shoulder and lipid core region of atherosclerotic plaques in human coronary arteries, and another study [161] had detected sub-endothelial CD68 + myofibroblasts in the lipid-rich areas of the atherosclerotic intima in human aorta. In light of the more recent observations [159] , it is reasonable to hypothesize that these cells were actually fibrocytes undergoing further differentiation into more mature mesenchymal cells and still expressing markers of the monocyte lineage. Further studies are needed to understand the relative contribution of fibrocytes to the development of the fibrous cap in atherosclerotic plaques and to investigate the potential role of these cells in the healing of plaque fractures.
Cancer-Induced Stromal Reactions
Myofibroblasts participate in cancer-induced stromal reactions and are considered to be major drivers of cancer growth and invasiveness [162] . Studies in mice [65, 163] have suggested that some of these cells may originate from fibrocytes. CD45 + CD34 --SMA + cells of bone marrow origin have been identified as an important component of cancer-induced stroma in the advanced stage of development of an implanted carcinoma in bone marrow chimeric mice [65] and such cells show the phenotype of fibrocytes undergoing further differentiation into mature myofibroblast-like cells [53, 62] . Moreover, the CCR5/CCL3 axis seems to regulate the development of the lung metastasis of invasive carcinomas in mice, and deficiency of the CCR5 or CCL3 gene has been reported to reduce the number of metastasis foci and the intratumoral accumulation of macrophages and fibrocytes in these animals [163] . The ability of fibrocytes to release BM-degrading enzymes and pro-angiogenic growth factors (Fig. (3) ) is also in support of the hypothesis that such cells may potentially contribute to the metastatic progression of invasive tumors [53, 163] . However, the numerous studies conducted in humans have provided inconclusive results. According to the findings of most of these studies [30, [41] [42] [43] [44] [45] [46] [47] [48] [49] , CD34
+ -SMA -spindle-shaped cells, resembling fibrocytes, are usually found in the stroma encapsulating benign tumours, while CD34 --SMA + fibroblasts are particularly frequent around invasive carcinoma. These observations would suggest that human fibrocytes are not an important component of cancer-induced stroma. Taking into account the antigen-presenting properties of fibrocytes and their ability to activate cytotoxic CD8 + T cells (Fig. (3) ), it has been proposed that the disappearance of CD34 + fibrocyte-like cells from the stroma of invasive tumors might be induced by the cancer and might constitute a step in escaping the host's immune control [164] . However, the apparent loss of CD34 + fibrocyte-like cells and the concomitant increase in the number of -SMA + CD34 -cells in the stroma surrounding malignant lesions [41, 45, 47] may also reflect an increased differentiation of CD34 + fibrocytes into CD34 -myofibroblast-like cells as a result of the exposure to the high amounts of TGF-1 and ET-1 produced in the cancer micro-environment [49, 165] . A recent study [166] demonstrated the presence of mesenchymal progenitors in the pulmonary artery blood of patients with histologically proven lung cancer, who were not receiving chemotherapy. These cells were CD105-positive and did not show CD14 immunoreactivity, although they expressed CD14 and other markers of the monocyte lineage at the gene level. Under appropriate culture conditions, such cells gave rise to mature mesenchymal cells, expressing collagen I and -SMA, and to adipocytes and osteocytes. The myofibroblast-like cells derived from the mesenchymal progenitors in long-term cultures were CD45 low/-CD34 -but retained CD105 expression. Taken together, these data suggest that the circulating progenitor detected in this study may represent an intermediate stage of differentiation into a committed mesenchymal progenitor of the multipotent precursor from which fibrocytes originate, probably an immature fibrocyte. The results of this study would therefore support the hypothesis that fibrocytes are involved in the cancer-induced stromal reactions. In a previously published paper describing the structural and functional aspects of melanoma-stroma interaction [167] it was suggested that tumor cells may suggested that tumor cells may induce the recruitment of circulating mesenchymal or multipotent precursors and induce their differentiation into either fibrocytes or myofibroblasts. The fibrocytes located in the center of the tumor would provide a scaffold for tumor cells, while the myofibroblasts present in the outer rim of the tumor would promote cancer growth and invasiveness [167] . Further characterization of the circulating mesenchymal precursor and its progeny may help clarify the role of fibrocytes in cancer progression.
CONCLUSIONS AND IMPLICATIONS FOR CELL THERAPY
Following the first description of fibrocytes [16] and their unequivocal identification in two human disorders [27, 31] , numerous studies have been conducted to evaluate the involvement of these cells in some animal models of human diseases and in various human pathologic conditions. The available data indicate that human fibrocytes may serve as a renewable source of fibroblast-and myofibroblast-like cells in conditions requiring, or inappropriately demanding an extra source of these cells, including the repair of extensive tissue damage, aberrant reparative processes in predisposed individuals, fibrotic disorders caused by persistent tissue injury, and diseases characterized by the uncontrolled and progressive fibrotic replacement of the normal tissue architecture [53, 62] . In these situations, the accumulation of fibrocytes at tissue sites may have either beneficial or detrimental effects, depending on the nature of the inciting event and the host response [53] . Some of the signals that may promote or inhibit the maturation of fibrocytes and their differentiation into lesional fibroblasts and myofibroblasts have been defined (Fig. (1), (2) ) and may serve as therapeutic targets [53, 62] . Inhibitors of IL-4 and IL-13, TGF-antagonists and ET-1 receptor antagonists are currently under development for the treatment of asthma [75] or IPF [168] . IFN-2b seems to represent a promising therapeutic option for the treatment of post-burn hypertrophic scars [54] . In the murine model of bleomycin-induced pulmonary fibrosis, the administration of exogenous SAP, either before or following the intra-tracheal injection of bleomycin, markedly reduces the accumulation of fibrocytes in the lungs and this effect is associated with reduced deposition of collagen in the interstitium and reduced loss of functional parenchyma [66] . SAP is a protein normally present in human serum and the administration of exogenous SAP to patients with fibrotic disorders like IPF may halt disease progression without provoking significant side effects. Fibrocytes express the chemokine receptors CCR5, CCR7 and CXCR4 and migrate in vitro in response to the corresponding ligands CCL3-CCL5, CCL19-CCL21 and CXCL12. Inhibition of signaling through these receptors has resulted in the prevention of injury-induced fibrotic reactions in various animal model of pulmonary or renal fibrosis [34, 39, 61] and may be useful in disorders characterized by a high mortality rate like IPF. It is however to be considered that such receptors are also expressed by cells critically involved in adaptive immune responses, host protection against infections, killing of intracellular pathogens and tumor resistance [72] [73] [74] 169] . Therefore, the selection of these receptors as therapeutic target for inhibiting or facilitating fibrocyte accumulation and differentiation at tissue sites in non-fatal disorders may not represent a sufficiently safe approach [53] .
Relatively high numbers of fibrocytes can be easily obtained in cultures of circulating CD14 + mononuclear cells and these cells can be further expanded by repeated passages without changing their phenotypic and functional characteristics. Moreover, tracking experiments in a murine model of wound healing [18] and in a model of chronic allergic asthma [27] have demonstrated that intravenously injected fibrocytes rapidly migrate to wounded or chronically inflamed sites and localize to areas of ongoing ECM deposition [18, 27] . For these reasons, cell therapy with autologous fibrocytes may potentially represent a safe and effective approach for the treatment of certain conditions that do not require many repeated interventions [53] . In particular, expanded autologous fibrocytes may be used for accelerating the healing of acute tissue injuries, such as extensive burns or lung tissue damage resulting from the inhalation of toxic agents [53, 62] . Expanded autologous cells may also serve as vehicles for the delivery of therapeutic gene constructs to improve ineffective repair processes [53, 62] . Fibrocytes are present in the stroma encapsulating benign tumors but may also participate in the cancer-induced stromal reactions. It is still unclear if these cells inhibit or promote cancer progression. However, expanded fibrocytes could be potentially used in anti-cancer cell therapy to encapsulate tumors and prevent their invasion as well as for the delivery of cytotoxic compounds to kill cancerous cells [53, 62] .
